Palopegteriparatide treatment for hypoparathyroidism in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy: a case series and literature update.

Akers H, Maxey L, Ashley K, Lima F, Rao M

JBMR plus21 Jul 2026

PMID42614145PMCIDPMC13481145DOI10.1093/jbmrpl/ziag114PepBankPUB-42614145

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanCase report or seriesEfficacy outcome
In patients with APECED-associated hypoparathyroidism, palopegteriparatide produced a robust calcemic response during follow-up.
In plain wordsIn patients with APECED-associated hypoparathyroidism, calcium responded to palopegteriparatide during follow-up.
Peptide
Palopegteriparatide
Outcome
Direction not reportedCalcemic response
Study
n = 4
Outcome group
Electrolyte balance · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
We observed a robust calcemic response to treatment during this follow-up window with wide fluctuations in serum calcium during this period of dose titration.
1 context sentence(design, population, supporting numbers)
Summary · context
We report our experience in 4 patients with APECED-associated hypoPT who initiated treatment with palopegteriparatide and were followed over the subsequent 4-15 mo period.
Report a problemFND-4261414501
02HumanCase report or seriesEfficacy outcome
In patients with APECED-associated hypoparathyroidism, serum calcium fluctuated widely during palopegteriparatide dose titration.
In plain wordsIn patients with APECED-associated hypoparathyroidism, serum calcium fluctuated widely during palopegteriparatide dose titration.
Peptide
Palopegteriparatide
Outcome
MixedSerum calcium fluctuations
Study
n = 4
Outcome group
Electrolyte balance · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
We observed a robust calcemic response to treatment during this follow-up window with wide fluctuations in serum calcium during this period of dose titration.
1 context sentence(design, population, supporting numbers)
Summary · context
We report our experience in 4 patients with APECED-associated hypoPT who initiated treatment with palopegteriparatide and were followed over the subsequent 4-15 mo period.
Report a problemFND-4261414502
03HumanCase report or seriesEfficacy outcome
In patients with APECED-associated hypoparathyroidism, palopegteriparatide was reported to enable discontinuation of oral calcium supplements.
In plain wordsIn patients with APECED-associated hypoparathyroidism, palopegteriparatide was reported to allow oral calcium supplements to be stopped.
Peptide
Palopegteriparatide
Outcome
DecreaseOral calcium discontinuation
Study
n = 4
Outcome group
Conventional therapy requirements · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
These early observations highlight the effectiveness of palopegteriparatide in patients with APECED, enabling the discontinuation of oral calcium and active vitamin D supplements.
1 context sentence(design, population, supporting numbers)
Summary · context
We report our experience in 4 patients with APECED-associated hypoPT who initiated treatment with palopegteriparatide and were followed over the subsequent 4-15 mo period.
Report a problemFND-4261414503
04HumanCase report or seriesEfficacy outcome
In patients with APECED-associated hypoparathyroidism, palopegteriparatide was reported to enable discontinuation of active vitamin D supplements.
In plain wordsIn patients with APECED-associated hypoparathyroidism, palopegteriparatide was reported to allow active vitamin D supplements to be stopped.
Peptide
Palopegteriparatide
Outcome
DecreaseActive vitamin D discontinuation
Study
n = 4
Outcome group
Conventional therapy requirements · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
These early observations highlight the effectiveness of palopegteriparatide in patients with APECED, enabling the discontinuation of oral calcium and active vitamin D supplements.
1 context sentence(design, population, supporting numbers)
Summary · context
We report our experience in 4 patients with APECED-associated hypoPT who initiated treatment with palopegteriparatide and were followed over the subsequent 4-15 mo period.
Report a problemFND-4261414504

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.